Most breast cancer neoadjuvant therapy is still effective, and a small number of those with poorer results should change their treatment in time. Patients with large breast cancer lesions, accompanied by lymph node metastasis, and willingness to preserve breast need to use neoadjuvant chemotherapy to shrink the lesions, improve the surgical resection rate and obtain better cosmetic results. The 2 cycles of neoadjuvant therapy must pay attention to the evaluation of the efficacy, most of the neoadjuvant therapy results are still relatively satisfactory, a small number of patients will have disease progression, these patients are not sensitive to neoadjuvant therapy, and they should be timely switched to other methods of treatment, such as surgical treatment. Therefore, although most patients benefit from neoadjuvant therapy, it should be closely evaluated, and if the treatment is ineffective and leads to disease progression, the treatment should be changed in a timely manner under the guidance of the doctor.